Description

I am a global medical affairs leader with strong scientific interest and acumen. Experienced team builder across different cultures and geographies, while also understand and ready to support the business requirements.

I have worked on 3 out of the 16 approved gene and cell therapy medications in Europe including launching them. I created and implemented globsal company wide procedures to supply these products in high unmet medical indications in the EU and Japan.

My broad knowledge of medical affairs across several therapeutic ares and geographies makes me a versatile and flexible candidate in "need to start immediately" scenarios.

Industry field of expertise

Languages

English
Native or bilingual
German
Basic
Hungarian
Native or bilingual

Workplace preferences

Can work on-site

Zug (up to 50km)

BMS
Worldwide Senior Medical Director
BIOTECH
December 2021 - October 2024 (2 years and 10 months)
Boudry, NE, Switzerland
Cell therapy senior medical director leading worldwide (ex-US PANCART medical affairs strategy, including apheresis guidance, non-conforming product release in the EU.
Secondary primary malignancy global transgene assay study protocol development, leading early (expanded) access protocols and PASS RWE studies.
BMS medical point of contact to EBMT and T2/Evolve EU-funded IMI project
CART operational medical team member in cell therapy franchise workstreams Patient Operations, Apheresis Operations, Quality, Manufacturing Science, Affiliate Medical) and disease MM, NHL teams. Developed and approved cell therapy related scientific training and content for external use.
Conducted global Advisory Board meetings.
Medical author and/or approver of EU/US regulatory documents and responses.
Launch experience in the EU, Switzerland, Japan and Canada with Abecma in multiple myeloma and Breyanzi in NHL.
cell therapy global disease registry release of non-conforming product product launch budget ownership
Amgen Europe GmbH
Medical Director
September 2009 - February 2019 (9 years and 5 months)
Zug, Switzerland
•
•
•
•
•
•
• Launch of Imlygic TVEC gene modified oncolytic virus in metastatic melanoma Evidence generation in hematology with Neulasta/Neupogen: stem cell mobilization & transplantation, DLBCL, breast cancer EU launch of Kyprolis: proteasome inhibitor in multiple myeloma Supervised direct reports up to 4 colleagues (clinical scientist, medical communications) Led European medical affairs strategy including evidence generation, publications, scientific communication, partnering with brand team & market access & pricing Attended CHMP/CAT oral hearings
MSD International
Executive Medical Director
PHARMACEUTICALS INDUSTRY
March 2019 - September 2021 (2 years and 6 months)
Kriens, LU, Switzerland
Global medical affairs lead in oncology responsible for gastrointestinal and
hematological malignancy portfolio and medical affairs strategy.
Six global and regional medical affairs director direct reports.
Responsible for global medical affairs strategy and launch execution.
Medical lead for the oncology portfolio Keytruda in gastric, esophageal and colorectal cancer; Lenvima in hepatic cancer; Lynparza in pancreatic cancer) and hematology pipeline assets (reversible non-covalent BTKi in CLL, Keytruda in Hodgkin's disease).
Merck/MSD medical point of contact to global external scientific leaders and medical societies.